Skip to main content
SpringerLink
Log in

Non-Specific Exogenous Immunomodulator in Oncology

  • Chapter
Principles of Cancer Biotherapy

  • 108 Accesses

Abstract

A few decades of cancer chemotherapy practice [41] have shown that it can, alone or combined to other means of tumor treatments (surgery and radiotherapy), cure a remarkable proportion of malignant neoplasias in children (osteosarcoma, neuroblastoma under one year of age, rhabdomyosarcoma, Wilm’s tumor, acute lymphoid leukemia) and in young adults (testis seminoma, teratocarcinoma and embryocarcinoma) [138], while it only contributes a little, if at all, [278,43,145,139] to the cure of adults older than 40 years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alonso K, Pontiggia P, Nardi C. Systemic hyperthermia in the treatment of HIV-related Kaposi’s sarcoma. A phase 1 study. 19th Intern Symp Clinical Hyperthermia, Dubna, Mai 1991.

    Google Scholar 

  2. Amoscato AA, Balasubramaniam A, Alexander JW, Babcok GF. Degradation of thymopentin by human lymphocytes: evidence for aminopeptidase activity. Biochim Biophys Acta 1988; 955: 164–174.

    Article  PubMed  CAS  Google Scholar 

  3. Amoscato AA, Davies PJA, Babcock GF, Nishioka K. Receptor-mediated internalization of tuftsin. In Anon: Conf antineoplastic, immunogenic and other effects of the tetrapeptide tuftsin: A natural macrophage activator. New York: February 16-17,1983 (abstract n° 11).

    Google Scholar 

  4. Andrieu JM. Biologie des cancers. Paris: Ellipses/Aupelf, 1994.

    Google Scholar 

  5. Arnaud J, Adlof M, Buyse M. Double blind trial of levamisole in colon cancer. Cancer Immunol Immunother 1986; 23 (suppl): A4 (abstr)

    Google Scholar 

  6. Asselinean J, Portelance V Comparative study of the free lipids of BCG daughter strain. In: Rentchnick P, ed. Investigation and Stimulation of Immunity in Cancer Patients. New York: Springer, 1974:214–217.

    Google Scholar 

  7. Astashkin EI, Prikhod’ko AZ, Kosheleva NA, Pautova IG, Nikolaeva IS. Effects of dibasol and levamisole on the microsomal enzyme system. Farmakologiia I Toksikologiia 1987; 50:75–76.

    PubMed  CAS  Google Scholar 

  8. Baker D, Sager H, Constable W. The influence of levamisole and hyperthermia on the incidence of metastases from an x-irradiated tumor. Cancer Invest 1986; 4: 287–292.

    Article  PubMed  CAS  Google Scholar 

  9. Baltimore D. Tumor viruses 1974. Cold Spring Harbor Symp 1975; 39: 1187–1200.

    Google Scholar 

  10. Bar-Shavit Z, Teitelbaum SL, Reitsma P, Hall A, Pegg LE, Trial J, Kahn, AJ. Induction of monocytic differentiation and bone resorption by 1, 25-dihydroxy vitamin D3. Proc Natl Acad Sci USA 1983; 80: 5907–5911.

    Article  PubMed  CAS  Google Scholar 

  11. Bartik MM, Ahn MC, Baumgartel BA, Hendricks RL, Mokyr MB. Presence of an enlarged pool of MOPC-315- specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. Cancer Immunol Immunother 1990; 32:43–53.

    Article  Google Scholar 

  12. Bataille R, Chappard D, Klein B. The critical role of interleukin-6, interleukin-IB and macrophage colonystimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 1992; 21: 283–287.

    Article  PubMed  CAS  Google Scholar 

  13. Beers RF, Braun W. Biological Effects of Polynucleotides. Heidelberg: Springer, 1971.

    Google Scholar 

  14. Bekesi JG, St Artneault G, Holland JF. Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res 1971; 31: 2130–2132.

    PubMed  CAS  Google Scholar 

  15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of acute leukaemias. Br J Haematol 1976; 33: 451–458.

    Article  PubMed  CAS  Google Scholar 

  16. Besa EC, Abraham JL, Novell PC. Combination of 13-cisretinoic acid and alpha-tocopherol for the chronic phase of myelodysplasia. Third Int Conf Prev Human Cancer 1988; S4: 13.

    Google Scholar 

  17. Biggar RJ, Horm J, Lubin JH, Goedert JJ, Greene MH, Fraumeni Jf, Jr. Cancer trends in a population at risk of acquired immuno-deficiency syndrome. J Natl Cancer Inst 1985; 74: 793–797.

    PubMed  CAS  Google Scholar 

  18. Blazsek I, Mathe G. Zinc and immunity. Biomed Pharmacother 1984; 38: 187–193.

    PubMed  CAS  Google Scholar 

  19. Blazsek I, Misset JL, Benavides M, Comisso M, Ribaud P, Mathé G. Hematon, a multicellular functional unit in normal human bone marrow: structural organization, hemopoietic activity and its relationship to myelodysplasia and myeloid leukemias. Exp Hematol 1990; 18: 259–265.

    PubMed  CAS  Google Scholar 

  20. Blomgren H, Edsmyr F, Esposti PL, Naeslund I. Immunological and hematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial. Biomed Pharmacother 1984; 38: 143–149.

    PubMed  CAS  Google Scholar 

  21. Blomgren H, Edsmyr F, vonStedingk LV, Wasserman J. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients. Biomed Pharmacother 1986; 40: 50.

    PubMed  CAS  Google Scholar 

  22. Blumenstein M, Layne PP, Najjar VA, Nuclear magnetic resonance studies on the structure of the tetrapeptide tufstin, L-threonyl-L-lysyl-L-propyl-L-arginine, and its pentapeptide analogue, L-threonyl-L-lysyl-L-propyl-Lpropyl- L-arginine Biochemistry 1979; 18: 5247–5253.

    Article  PubMed  CAS  Google Scholar 

  23. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment of operable breast cancer. N Engl J Med 1976; 294:405–410.

    Article  PubMed  CAS  Google Scholar 

  24. Bonadonna G, Rossi A, Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. Lancet 1985;i: 976–977.

    Article  Google Scholar 

  25. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The result at 20 years follow up. N Engl J Med 1995; 332: 901–906.

    Article  PubMed  CAS  Google Scholar 

  26. Bortin MM, Rimm AA, Saltzstein EC. Cell-mediated immunity in AKR mice treated with lentinan, a fungal polysaccharide. In: Rentchnick P, ed. Investigation and Stimulation of Immunity in Cancer Patients. New York: Springer, 1974: 320.

    Google Scholar 

  27. Bortin MM, Rimm AA, Salzstein EC. Graft versus leuke mia quantitation of adoptive immunotherapy in murine leukemia. Science 1973; 179: 811–813.

    Article  PubMed  CAS  Google Scholar 

  28. Bourut C, Chenu E, Mathe G. Can neo-adjuvant chemotherapy prevent residual tumors. J Med Oncol Tumors Pharmacother 1988; 259-63.

    Google Scholar 

  29. Bravo-Cuellar A, Balercia G, Levesque JP, Liu XH, Osculati F. Orbach-Arbouys S. Enhanced activity of peritoneal cells after aclacinomycin injection: effect of pretreatment with superoxide dismutase on aclacinomycin- induced cytological alterations and antitumoral activity. Cancer Res 1989; 49: 1578–1586.

    PubMed  CAS  Google Scholar 

  30. Bravo-Cuellar A, Homo-Delarche F, Ramos-Zepeda R, Dubouch P, Cabannes J, Orbach-Arbouys S. Increased phagocytic activity of peripheral blood monocytes after intravenous injection of phospholipase A2 to monkeys. Immunol Letters 1991; 28: 5–9.

    Article  CAS  Google Scholar 

  31. Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Davigny M, Mathé G. Age related changes of the immune response and immuno-restoration by stimulating agents Doria G, Eshkol A, eds. The Immune System: Functions and therapy dysfunction? New York: Academic Press, 1980: 171–187.

    Google Scholar 

  32. Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Mathé G. Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology 1979; 38:75–83.

    PubMed  CAS  Google Scholar 

  33. Bruley-Rosset M, Florentin I, Kiger N, Schulz JI, Mathe G. Correction of immunodeficiency in aged mice by levamisole and bestatin administration. Rec Res Cancer itesl980; 75: 139-146.

    Google Scholar 

  34. Bruley-Rosset M, Florentin I, Mathé G. Effects of BCG and levamisole on immune response in young adult and aged-immunosuppressed mice. Cancer Treat Rep 1978; 62: 1641–1644.

    PubMed  CAS  Google Scholar 

  35. Bruley-Rosset M, Hercend T. Immunorestorative capacity of tuftsin after long-term administration to aging mice. Ann NY Acad Sci 1983; 419: 242–247.

    Article  PubMed  CAS  Google Scholar 

  36. Bruley-Rosset M, Hercend T, Martinez J, Rappaport H, Mathé G. Prevention of spontaneous tumors of aged mice by immuno-pharmacologic manipulation: Study of immune antitumor mechanism. J Natl Cancer Institute 1981;66:1113–1119.

    CAS  Google Scholar 

  37. Bruley-Rosset M, Rappaport H. Natural killer cell activity and spontaneous development of lymphoma. Effect of single and multiple injections of interferon into young and aged C57B1/6 mice. Int J Cancer 1983; 31: 381–389.

    Article  CAS  Google Scholar 

  38. Buschmans E. Personal communication.

    Google Scholar 

  39. Cassel WA, Murras DR, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 1977; 40: 672–679.

    Article  PubMed  CAS  Google Scholar 

  40. Catane R, Treves A J, Weiss L. Clinical phase I study of tuftsin. Proc Am Soc Clin Oncol 1983; 2: 45 (abstract C- 175).

    Google Scholar 

  41. Clarysse A, Kenis Y, Mathé G. Cancer chemotherapy. Its Role in the Treatment Strategy of Hematologic Malignancies and Solid Tumors. Heidelberg: Springer Verlag, 1976.

    Google Scholar 

  42. Cochrane CG, Studies on the localization of circulating antigen-antibody complexes and other macromolecules in vessels. I. Structural studies, J Exp Red 1963, 118-489-502

    Google Scholar 

  43. Cohen MM, Diamond JM. Medical research. Are we loosing the war on cancer? Nature 1986; 323:488–489.

    Article  PubMed  CAS  Google Scholar 

  44. Constantopoulos A. Congenital tuftsin deficiency. Ann NY Acad Sci 1983; 419: 214–219.

    Article  PubMed  CAS  Google Scholar 

  45. Constantopoulos A, Najjar VA, Smith JW. Tuftsin deficiency: A new syndrome with defective phagocytosis. JPediatr 1972; 80: 564–572.

    Article  CAS  Google Scholar 

  46. Cooperberg AA, Singer OP. Reversible myelofibrosis due to vitamine D deficiency rickets. Can Med Assoc J1980; 94: 392.

    Google Scholar 

  47. Coquerel A, Dubuc I, Kitabgi P, Costenti J. Potentiation by thiorphan and bestatin of the naloxone-intensive analgesic effects of neurotensin and neuromedin N. Neurochem Int 1988; 12:361.

    Article  CAS  Google Scholar 

  48. Culliton BJ. FDA panel backs interleukin 2 (news). Nature 1992; 355: 287.

    PubMed  CAS  Google Scholar 

  49. Deeg HJ, Erickson K, Storb R, Sullivan KM. Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow tranplantation. Blood Cells 1992; 18: 151–162.

    PubMed  CAS  Google Scholar 

  50. Degos L, Castaigne S, Chomienne C, Therapeutic trials of acute myeloid leukemia by retinoid acid. In: Waxman S, Ross GB, Takaka F, eds. Serono Symposia: Raven Press, 1988:45.

    Google Scholar 

  51. Dennert G. Immunostimulation by retinoic acid. Ciba Foundation Symposium 1985; 113: 117–131.

    PubMed  CAS  Google Scholar 

  52. Dillehay DL, Cornay WJ, Walia AS, Lamon EW. Effects of retinoids on human thymus-dependent and thymusindependent mitogenesis. Clinical Immunol Immunopathol 1989; 50: 100–108.

    Article  CAS  Google Scholar 

  53. Dillman RO. Antibody therapy. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker, 1991: 395–432.

    Google Scholar 

  54. Dinarello CA. Anti-cytokine strategies. Eur Cytokine Netw 1992;3:7–17.

    PubMed  CAS  Google Scholar 

  55. Dore JF, Diatloff C, Mathé G. Suppression of immunocompetent cells reactivity by incubation at 37°C. In White cell Transfusions. Paris: Centre National de la Recherche Scientifique, 1970: 10.

    Google Scholar 

  56. Ebihara T, Koyama S, Fukao K, Osuga T. Lymphokineactivated suppressor (LAS) cells in patients with gastric carcinoma. Cancer Immunol Immunother 1989; 28: 218–224.

    Article  PubMed  CAS  Google Scholar 

  57. Ershler W, Hacker M. Cimetidine and the immune response. Clin Immunol Immunopathol 1982; 26: 10–17.

    Article  Google Scholar 

  58. Favalli L, Lanza E, Rozza A, Galimberti M, Villani F. Evaluation of the cardiovascular toxic effect of recombinant interleukin-2 in rats. Anticancer Res 1990; 10: 1693–1698.

    PubMed  CAS  Google Scholar 

  59. Ferrari L, Jouzeau JY, Gillet P, Herber R, Fener P, Batt AM, Netter P. Interleukin-1 beta differentially represses drug-metabolizing enzymes in arthritic female rats. J Pharmacol Exper therapeutic 1993; 264: 1012–1020.

    CAS  Google Scholar 

  60. Fidalgo BV, Najjar VA. The physiological role of the lymphoid system. III. Leucophilic gamma-globulin and the phagocytic activity of the polymorphonuclear leucocyte. Proc Natl Acad Sci USA 1967; 57: 957–964.

    Article  PubMed  CAS  Google Scholar 

  61. Fidalgo BV, Najjar VA. The physiological role of the lymphoid system. VI. The stimulatory effect of leucophilic gamma-globulin (leucokinin) on the phagocytic activity of human polymorphonuclear leucocyte. Biochemistry 1967; 6: 3385–3392.

    Google Scholar 

  62. Fishbein GE. Immunotherapy of lung cancer. Semin Oncol 1993; 20: 351–358.

    PubMed  CAS  Google Scholar 

  63. Florentin I, Bruley-Rosset M, Davigny M, Mathé G. Comparison of the effects of BCG and a preparation of heat-killed Pseudomonas aeruginosa on the immune response in mice. In: Werner GH, Floch F, eds. The Pharmacology of Immunoregulation. New York: Academic Press; 1978: 335.

    Google Scholar 

  64. Florentin I, Bruley-Rosset M, Kiger N, Imbach JL, Winternitz F, Mathé G. In vivo immunostimulation by tuftsin. Cancer Immunol Immunother 1978; 5:211.

    Article  CAS  Google Scholar 

  65. Florentin I, Chung V, Davigny M, Mathé G. Immunomodulatory effects of bestatin in immunocompetent mice. In: Mathe G, Umezawa H, eds. Progress in Cancer Chemo-immunotherapy. Tokyo: Japan Antibiotics Research Association, 1984: 212.

    Google Scholar 

  66. Florentin I, Chung V, Martinez J, Maria J, LeGarrec Y, Mathé G. In vivo immunopharmacological properties of tuftsin (Thr-Lys-Prol-Arg) and some analogues. Meth FindExptl Clinic Pharmacol 1986; 8: 73–80.

    CAS  Google Scholar 

  67. Florentin I, Kiger N, Bruley-Rosset M, Schulz J, Mathé G. Effect of seven immunomodulators on different types of immune responses in mice. In Human Lymphocyte Differentiation. Amsterdam - North Holland: Biomedical Press, 1978: 299.

    Google Scholar 

  68. Freake HC, Marcocci C, Iwasaki J. 1, 25-dihydroxyvitamin D3 specifically binds to a human breast cancer cell line (T 47D) and stimulates growth. Biochem Biophys Res Comm 1981; 101: 1131–1138.

    Article  PubMed  CAS  Google Scholar 

  69. Fujisaki T, Otsuka T, Takamatsu Y, Eto T, Harada M, Niho Y. Effects of bestatin hematopoiesis in long-term human bone marrow cultures. Biomed Pharmacother 1995; 49: 69–74

    Article  PubMed  CAS  Google Scholar 

  70. Gabrilovac J, Martin-Kleiner I, Ikic-Sutlic M, Osmak M. Interaction of leu-enkephalin and alpha interferon in modulation of NK activity of human peripheral blood lymphocytes. Ann NY Acad Sc 1992; 650: 140–145.

    Article  CAS  Google Scholar 

  71. Galazka AR, Weiner J, Barth NM, Oldham RK. Lymphokines and cytokines. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker, 1991: 327–361.

    Google Scholar 

  72. Gallagher JC, Jerpback CM, Jee WS, Johnson KA, Deluca HF, Riggs BL. 1,25-dihydroxy-vitamin D3: shortand long-term effects on bone and calcium metabolism in patients with post menopausal osteoporosis. Proc Natl Acad Sci USA 1982; 79: 3325–3329.

    Article  PubMed  CAS  Google Scholar 

  73. Garcia-Giralt E, Maciera-Coelho A. Methoxy-9-ellipticine. II. Analysis in vitro of the mechanism of action. Rev EuropEtud Clin Biol 1970; 15: 539–541.

    CAS  Google Scholar 

  74. Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V, Pfreundschuh M. Low serum interleukin-2 receptor levels correlated with a good prognosis in patients with Hodgkin’s lymphoma. Ann Oncology 1991; 2 suppl 2:43–47.

    Google Scholar 

  75. Geffard M, Orbach-Arbouys S. Enhancement of Tsuppressor activity in mice by high doses of BCG. Cancer Immunol Immunother 1976; 1:41–44.

    Article  Google Scholar 

  76. Gerosa MA, Olivi A, Rosenblum ML, Semenzato GP, Pezzutto A. Impaired immunocompetence in patients with malignant gliomas: the possible role of Tg-lymphocyte subpopulations. Neurosurgery 1982; 10: 571–573.

    Article  PubMed  CAS  Google Scholar 

  77. Gidlund M, Orn A, Wigzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978; 273: 759–761.

    Article  PubMed  CAS  Google Scholar 

  78. Glover J. The conversion of beta-carotene into vitamin A. VitamHorm 1960; 18:371.

    Article  PubMed  CAS  Google Scholar 

  79. Goey H, Keller JR, Jansen R. Antiproliferative effects of transforming growth factor beta-1 for murine tumors and hematopoietic progenitor cells. Proc. Ann Meet Am Assoc Cancer Res 1989; 30: A1295 (abst).

    Google Scholar 

  80. Gorvel JP, Vivier I, Naquet P, Brekelmans P, Rigal A, Pierres M. Characterization of the neutral aminopeptidase activity associated to the mouse thymocyte-activating molecule. J Immunol 1990; 144: 2899–2907.

    PubMed  CAS  Google Scholar 

  81. Gottlieb P, Stabinsky Y, Hazyum E. Tuftsin Receptors. In Anon: Conf antineoplastic, imunogenic and other effects of the tetrapeptide tuftsin: A natural macrophage activator. New York, Februrary 16-17, 1983 (abstract n° 9).

    Google Scholar 

  82. Gottlieb P, Stabinsky Y, Zakuth V, Spirer Z, Fridkin M. Synthetic pathways to tuftsin and radioimmunoassay. In Anon: Conf antineoplastic, immunogenic and other effects of the tetrapeptide tuftsin: A natural macrophage activator. New York, Februrary 16-17, 1983 (abstract n° 2).

    Google Scholar 

  83. . Gouveia J, Mathe G, Hercend T, Gros F, Lemaigre G, Santelli G, Homasson JP, Gaillard JP, Angebault M, Bonniot JP, Lededente A, Marsac J, Parot R, Pretet S. Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoids. Lancet 1982; i: 1710–712.

    Google Scholar 

  84. Greeley EH, Helfrich BA, Feuerman LL, Cain CCA, Segre M. Radiant heat-induced hyperthermia in mice: in vivo effects on the immune system. Int J Hyperthrmia 1992;8:209–220.

    Article  CAS  Google Scholar 

  85. Haaksenstad AO, Mannik M. The biology of immune complexes. In: Talal N, ed. Autoimmunity. New York: Academic Press, 1977.

    Google Scholar 

  86. Hadden MJW, Hadden EM. Therapy of secondary T-cell immunodeficiencies with biological substances and drugs. Med Oncol Tumor Pharmacother 1989; 6: 11–17.

    PubMed  CAS  Google Scholar 

  87. Halle-Pannenko O, Abuaf N, Mathé G. Use of soluble histocompatibility antigen(s) in the control of transplantation reaction: possible dissociation of the roles of H-2 and non H-2 antigens in the prevention of mortality induced by graft-versus-host reactions. Transpl Proc 1976; 8: 161–172.

    CAS  Google Scholar 

  88. Halle-Pannenko O, Martyre M-C, Mathé G. Prevention of graft-versus-host reaction by donor pretreatment with soluble H-2 antigens. Transplantation 1971; 2:414–417.

    Article  Google Scholar 

  89. Hang LM, Aguado MT, Dixon FJ, Theofilopoulos AN. Induction of severe autoimmune disease in normal mice by simultaneous action of multiple immunostimulators. J Exp Med 1985; 161:423–428.

    Article  PubMed  CAS  Google Scholar 

  90. Harms BA, Rosenfeld DJ, Conhaim RL, Pahl AC, Subramanian R, Storm FK. Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion. Surgery 1991; 110: 500–507.

    PubMed  CAS  Google Scholar 

  91. Haussler MR, Baylink DJ, Hughes MR, Brumbaugh PF, Wergedal JE, Shen FH, Nielsen RL, Counts SJ, Bursac KM, Mc Cain TA. The assay of 1-alpha, 25-dihydroxy vitamin D3: Physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol 1979; 5(supp): 151S–165S.

    Google Scholar 

  92. Hawkins MM. Long term survival and cure after childhood cancer. Arch Dis Child 1989; 64: 798–807.

    Article  PubMed  CAS  Google Scholar 

  93. Hayes TJ. Progress and challenges in the preclinical assessment of cytokines. Toxicol Letters 1992; 64-65. spec. n° 291-7.

    Google Scholar 

  94. Hemmi H, Breitman TR. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987; 69: 501–507.

    PubMed  CAS  Google Scholar 

  95. Herman ZS, Stachura Z, Opielka L, Siemion IZ, Nawrocka E. Tuftsin and D-Arg3-tuftsin possess analgesic action. Experientia 1981; 37: 76–77.

    Article  PubMed  CAS  Google Scholar 

  96. Hoerni B, Durand M, Eghbali H, Hoerni-Simon G, Lagarde C. Adjuvant BCG-therapy of non Hodgkin’s malignant lymphomas. In: Salmon SE, Jones SE, eds. Adjuvant Therapy of Cancer III. New York: Grune & Stratton, 1981: 99.

    Google Scholar 

  97. Holcombe RF, Stewart RM, Betzing KW, Kannan K. Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 1994; 38: 394–398.

    Article  PubMed  CAS  Google Scholar 

  98. Hoover RN. Bacillus Calmette Guerin vaccination and cancer prevention: A critical review of the human experience. Cancer Res 1976; 36: 652–654.

    PubMed  CAS  Google Scholar 

  99. Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, Zhao L, Xie JX, Shen ZX, Wang ZY. All-trans-retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J 1987; 100: 949–953.

    PubMed  CAS  Google Scholar 

  100. Huchet R, Florentin I, Mathé G. Mechanism of action of BCG as an immunity adjuvant used in cancer active immunotherapy. Proc Amer Assoc Cancer Res 1976; 17: 160 (abst).

    Google Scholar 

  101. Hughes RC, Sanford BH, Jeanloz RW. Regeneration of the surface glycoproteins of a transplantable mouse tumor cell after treatment with neuraminidase. Proc Natl Acad Sci USA 1972; 69: 942–945.

    Article  PubMed  CAS  Google Scholar 

  102. Hui IJ. MAAF, a fully water-soluble lipid-free fraction from BCG with adjuvant and antitumor activity. In: Rentchnick P, ed. Investigation and Stimulation of Immunity in Cancer Patients. New York: Springer, 1974: 213.

    Google Scholar 

  103. Hunter T, Cooper JA. Protein tyrosine kinases. Ann Rev Biochem 1985; 54: 897–930.

    Article  PubMed  CAS  Google Scholar 

  104. Inada K, Nemeto N, Nishijima A, Wada S, Hirata M, Yoshida M.A case suspected of tuftsin deficiency. In: Yoshida MA. Phagocytosis: Its physiology and pathology. Baltimore: University Park Press, 1979: 158.

    Google Scholar 

  105. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocytic response by transforming growth factor beta. Cancer Res 1992;52:1386–1392.

    PubMed  CAS  Google Scholar 

  106. Ishizuka M, Masuda T, Kanbayashi N, Fukasawa S, Takeuchi T, Aoyagi T, Umezawa H. Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot 1980; 33: 642–652.

    PubMed  CAS  Google Scholar 

  107. Jin Z, Kumar A, Cleveland RP, Murray DL, Kaufman DB. Inhibition of suppressor cell function by cimetidine in an murine model. Clin Immunol Immunopathol 1986; 38: 350–356.

    Article  PubMed  CAS  Google Scholar 

  108. Joseph RR, Belpomme D, Mathe G. Increase in ’null’ cells in acute lymphocytic leukaemia in remission on longterm immunotherapy. Br J Cancer 1976; 33: 567–570.

    Article  PubMed  CAS  Google Scholar 

  109. Kable T, Beer M, Mendoza E, Ikinger U, Link M, Reichert HE, Frangenheim T, Klein E, Fabricius PG. BCG vs interferon alpha for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urol Ausg A 1994; 33: 133.

    Google Scholar 

  110. Kaufman M, Marquerson J, Stanley K, Mouritzen C, Hansen H. Distribution of C parvum in man. Cancer Immunol Immunother 1986; 22: 56–61.

    Article  Google Scholar 

  111. Kendrick M, Comstock G. BCG vaccination and cancer in humans. J Natl Cancer Inst 1981; 66:431–437.

    PubMed  CAS  Google Scholar 

  112. Kenny AJ, Stephenson SL, Turner AJ. Cell surface peptidase. In: Kenny AJ, Turner AJ, eds. Mammalian Ectoenzymes. Amsterdam: Elsevier Science Publishers, 1986: 169.

    Google Scholar 

  113. Khatsenko OG, Gross SS, Rifking AB, Vane JR. Nitric oxide is a mediator of the decrease in cytochrome P-450- dependent metabolism caused by immunostimulants. Proc Natl Acad SciU SA1993;90: 11147–11151.

    Article  Google Scholar 

  114. Kimmel DW, Wijdicks EF, Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 1995; 45: 374–376.

    PubMed  CAS  Google Scholar 

  115. Kohne-Wompner CH, Schoffski P, Schmoll HJ. Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. Ann Oncol 1994; 5 (suppl 3) 97–104.

    PubMed  Google Scholar 

  116. Kolb J-PB, Senik A, Castagna M. In vitro stimulation of mouse NK cell activity by phorbol esters: a pathway different from interferon-induced activation. Cellular Immunol 1981; 65: 258–264.

    Article  Google Scholar 

  117. Komada Y, Azuma E, Yamamoto H, Tanaka S, Shimizu K, Kamiya H, Sakurai M, Izawa T. Discontinuing chemoimmunotherapy in childhood acute lymphoblastic leukemia. BiomedPharmacother 1988; 42: 597–603.

    PubMed  CAS  Google Scholar 

  118. Konznetzova B, Bizzini B, Cherman JC. Immunostimulating activity of whole cells, cell walls and fractions of anaerobic corynebacteria. In: Rentchnick P, ed. Investigation and Stimulation of Immunity in Cancer Patients. New York: Springer, 1974: 275.

    Google Scholar 

  119. Kopinska D, Luczak M, Wleklik M, Gomulka S, Kazanowska B. Elongated tufstin analogues: Synthesis and biological investigations. Ann NY Acad Sci 1983; 419: 35–43.

    Article  Google Scholar 

  120. Lacour J, Lacour F, Ducot B, Spira A, Michelson M, Petit J-Y, Sarrazin D, Contesso G. Polyadenylic-polyuridylic acid as adjuvant in the treatment of operable breast cancer: recent results. Eur J Surg Oncol 1988; 14: 311–316.

    PubMed  CAS  Google Scholar 

  121. Lacour J, Lacour F, Flamand R. Essai therapeutique sur le cancer mammaire spontane: chirurgie et ARN synthetique poly A: poly U). Chir 1970; 96: 364–368.

    CAS  Google Scholar 

  122. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage FG, Sarrazin D, Contesso G, Viguier J. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancert. Lancet 1980; ii: 161–164.

    Article  Google Scholar 

  123. Lamm DL. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur Urol 1992; 21 suppl.2: 12–16.

    PubMed  Google Scholar 

  124. . Lang J, Oberline F, Aleksijevic A, Falkendordt A, Mayer S. Immunomodulator with imuthiol in AIDS. Cancer Immunol Immunother 1986; 23 (suppl): A42 (abstr).

    Google Scholar 

  125. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment group and the Mayoclinic. J Clin Oncol 1989; 7: 1447–1156.

    PubMed  CAS  Google Scholar 

  126. Lederer E. From natural products chemistry to immunopharmacology. In Chedid L, Hadden JW, Spreafico F, Dukor P, Willoughby D, eds. Advances in Immunopharmacology 3. Proceeding of the Third International Conference on Immuno-pharmacology. Florence, May 6-9, 1985. Pergamon Press, 1986: 3-12.

    Google Scholar 

  127. Lee A. Effect of neuraminidase on the phagocytosis of heterologous red cells by mouse peripheral macrophages. Proc Soc Exp Biol Med 1968; 128: 891–894.

    PubMed  CAS  Google Scholar 

  128. Lehtinen M. Levamisole in maintenance of acute myeloid leukemia. Cancer Chemother Pharmacol 1980,5 (suppl): 28 (abstract 112).

    Google Scholar 

  129. Ley-Hausen G, Gramzow M, Zah RK, Steffen R, Umezawa H, Mueller WE. Immunochemical identification of the cell surface bound leucine aminopeptidase, the target enzyme for the immunostimulant bestatin. J Antibiot 1983; 36: 728–734.

    CAS  Google Scholar 

  130. Lichtenstein A, Berek J. Antitumor effects of pyridine extract from Propionibacter acnes. Cancer Immunol Immunother 1986; 22: 24–30.

    Article  PubMed  CAS  Google Scholar 

  131. Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp 150) is identical to aminopeptidase N.J Clin Invest 1989; 83 1299–1307.

    Article  CAS  Google Scholar 

  132. Lopez M. Adjuvant therapy of colorectal cancer. Dis Colon Rectum 1994; 37: S86–S91.

    Article  PubMed  CAS  Google Scholar 

  133. Martinez J, Winternitz F. New synthetic and natural tuftsin related compounds and evaluation of their phagocytosis- stimulating activity. Ann NY Acad Sci 1983; 419: 23– 34.

    Google Scholar 

  134. Mathé G. Are recombinant interleukins more or less therapeutically effective than their exogenous inducers? Biomed Pharmacother 1994; 48:413–415.

    Article  PubMed  Google Scholar 

  135. Mathé G. Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function. Biomed Pharmacother 1991;45:49–54.

    Article  PubMed  Google Scholar 

  136. Mathé G. Beta-endorphin inducers and their catabolism inhibitors in opioid addiction withdrawal. Biomed Pharmacother 1993; 47: 299–300.

    Article  PubMed  Google Scholar 

  137. Mathé G. Cancer Active Immunotherapy, Immunoprophylaxis and Immunorestoration. New York: Springer, 1976.

    Google Scholar 

  138. Mathé G. Cancer4 cures’ in children adolescent and young adults, versus general cancer cure failure after 50 years of age. Biomed Pharmacother 1988; 42: 227–236.

    PubMed  Google Scholar 

  139. Mathé G. Cancer therapy: it was by persisting that Greeks took troy. Biomed Pharmacother 1989; 43: 231–234.

    Article  PubMed  Google Scholar 

  140. Mathé G. Do tuftsin and bestatin constitute a biopharmacological immunoregulatory system? Cancer Detect Prevent 1987; suppl 1:445–455.

    Google Scholar 

  141. Mathé G. Don’t multiple drug and other cross resistances in cancer therapy compromise (phase 2) efficacy trials? Biomed Pharmacother 1993; 47: 361–362.

    Article  PubMed  Google Scholar 

  142. Mathé G. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants. Comp Immunol Microbiol Infect Disease 1980; 3: 407–432.

    Article  Google Scholar 

  143. Mathé G. Immunity, infection, malignancy and aging: possible immunity restoration and tumor prevention. Biomed Pharmacother 1989; 43: 541–543.

    Article  PubMed  Google Scholar 

  144. Mathé G. L’immunotherapie active de la leucemie L1210 appliquee apres la greffe tumorale. Rev Frang Etud Clin Biol 1968; 13:301.

    Google Scholar 

  145. Mathé G. Oncologists have lost a battle against cancer; biomedicine has not lost the war. Biomed Pharmacother 1986;40:370–371.

    PubMed  Google Scholar 

  146. Mathé G. Relationship between bestatin dose and the state of the CD8 lymphocyte number of immunologic responses in man. Biomed Pharmacother, submitted.

    Google Scholar 

  147. Mathé G. SIDA, sceaux, sexe, science. Paris: La Coutellerie; 1995.

    Google Scholar 

  148. Mathé G. The antigen and exogenous or endogenous immuno-modulator dose and the sens of the reaction. Biomed Pharmacother in preparation.

    Google Scholar 

  149. Mathé G, Amiel JL. Adoptive immunotherapy of acute leukemia. Experimental and clinical results. Cancer Res 1965;25:1525.

    PubMed  Google Scholar 

  150. Mathé G, Amiel JL, Schwarzenberg L. Treatment of total body irradiation injury in man. Ann NY Acad Sci 1964; 114:368–392.

    Article  PubMed  Google Scholar 

  151. Mathé G, Amiel JL, Bernard J. Traitement de souris AkR a Page de 6 mois par irradiation totale suivie de transfusion de cellules hematopoietiques homologues. Incidences respectives de la leucemie et du syndrome secondaire. Bull Cancer 1960; 47: 331.

    Google Scholar 

  152. Mathé G, Amiel JL, Cattan A, Schneider M. Haematopoietic chimera in man after allogeneic (homologous) bone marrow transplantation. Control of the secondary syndrome. Specific tolerance due to the chimerism. Br Med J 1963; 2: 1633.

    Article  PubMed  Google Scholar 

  153. Mathé G, Amiel JL, Niemetz J. Greffe de moelle osseuse apres irradiation totale chez des souris leucemiques, suivie de 1’administration d’un cytostatique pour reduire la frequence du syndrome secondaire et ajouter a l’effet antileucemique. CR Acad Sci (Paris) 1962; 255: 3602–3605.

    Google Scholar 

  154. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M, deVries MJ, Tubiana M, Lalanne C, Binet JL, Papiernik M, Seman G, Matsukura M, Mery AM, Schwarzmann BV, Flaisler A. Successful allogeneic bone marrow transplantation in man. Chimerism, induced specific tolerance and possible antileukemic effects. Blood 1965; 25: 179–196.

    PubMed  Google Scholar 

  155. Mathé G, Amiel JL, Schwarzenberg L, Mery AM. A method of reducing the incidence of the secondary syndrome in allogeneic marrow transplantation. Blood 1963;22:42–52.

    Google Scholar 

  156. Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, deVassal F. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; i: 697–699.

    Article  Google Scholar 

  157. Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Hayat M, deVassal F, Jasmin C, Rosenberg C, Sakouhi M, Choay J. Remission induction with poly IC in patients with acute lymphoblastic leukaemia (preliminary results). RevEurop Etudes Clin Biol 1970; 15: 671–673.

    Google Scholar 

  158. Mathé G, Amiel JL, Schwarzenberg L. Bone marrow transplantation and leukocyte transfusions. Springfield: Thomas, 1971.

    Google Scholar 

  159. Mathé G, Bernard J. Essai de traitement de la leucemie greffee L1210 par 1’irradiation X suivie de transfusion de cellules hematopoietiques normales (isologues ou homologues, lymphoi’des ou myeloYdes, adultes ou embryonnaires). Rev Frang Etud Clin Biol 1959; 4:442.

    Google Scholar 

  160. Mathé G, Bernard J. Essai de traitement par 1’irradiation X suivie de 1’administration de cellules medullaires homologues de souris AkR atteintes de leucemie spontanee tres avancee. Bull Cancer 1958; 45: 289.

    Google Scholar 

  161. Mathé G, Bernard J, Schwarzenberg L, Larrieu MJ, Lalanne C, Dutreix A, Denoix P, Schwarzmann V Ceoara B. Essai de traitement de sujets atteints de leucemie aigue par irradiation suivie de transfusion de moelle osseuse homologue. Rev Frang Etud Clin Biol 1959; 4: 615–704.

    Google Scholar 

  162. Mathé G, Bernard J, Schwarzenberg L, Larrieu MJ, Lalanne C, Dutreix A, Amiel JL, Surmont J. Nouveaux essais de greffe de moelle osseuse homologue apres irradiation totale chez des enfants atteints de leucemie aigue en remission. Le probleme du syndrome secondaire chez Thomme. Rev Hemat 1960; 15: 115–161.

    PubMed  Google Scholar 

  163. Mathé G, Bernard J, Tran Ba Loc. EfFet antileucemique de 1‘irradiation totale selon la dose d’irradiation et le nombre de cellules tumorales. Rev Frang Etudes Clin Biol 1960; 5:930.

    Google Scholar 

  164. Mathé G, Cattan A. Cancerologie. Paris:’Expansion Scientifique Frangaise. 1976.

    Google Scholar 

  165. Mathé G, deVries MJ, Amiel JL, Cattan A. Les divers aspects du syndrome secondaire compliquant les transfusions de moelle osseuse ou de leucocytes allogeniques chez des sujets atteints d’hemopathies malignes. Europ J Cancer 1965; 1:75.

    Article  Google Scholar 

  166. Mathé G, Eriguchi M. Scientific criticisms of the comparison of exponential survival and disease-free survival curves. Biomed Pharmacother 1988; 42: 177–186.

    PubMed  Google Scholar 

  167. Mathé G, Halle-Pannenko O, Bourut C. Active immunotherapy of AkR mice spontaneous leukemia. Rev Eur Etudes Clin Biol Res 1972; 17: 997–1000.

    Google Scholar 

  168. Mathé G, Halle-Pannenko O, Bourut C. BCG in cancer immunotherapy. II. Result obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy. Natl Cancer Int Monogr 1973; 39: 107.

    Google Scholar 

  169. Mathé G, Halle-Pannenko O, Bourut C. Effectiveness of murine leukemia chemotherapy according to the immune state: Reconsideration of correlation bewteen chemotherapy, tumour cell killing and survival time. Rec Res Cancer Res. 1977; 62: 9–12.

    Google Scholar 

  170. Mathé G, Halle-Pannenko O, Bourut C. Immune manipulation by BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukaemia. Eur J Cancer 1974; 10: 661–666.

    Article  PubMed  Google Scholar 

  171. Mathé G, Halle-Pannenko O, Bourut C. Interspersion of cyclophosphamide and BCG in the treatment of L1210 leukaemia and Lewis tumour. Eur. J. Cancer, 1977; 13: 1095–1098.

    Article  PubMed  Google Scholar 

  172. Mathé G, Hayat M, Sakouhi M, Choay J. L’action immuno-adjuvante du polylC chez la Souris, et son application au traitement de la leucemie L1210. CRAcad Sci 1971; 272: 170–173.

    Google Scholar 

  173. Mathé G, Itzhaki M, Orbach-Arbouys S. Bestatin specifically enhances the number of CD4+ T cells in peripheral blood in patients whose CD8+ T cell numbers are also depressed. Int J Immunotherapy 1993; 9: 165.

    Google Scholar 

  174. Mathé G, Kamel MK, Dezfulian M, Halle-Pannenko O, Bourut C. An experimental screening for ’systemic adjuvant of immunity’ applicable to cancer immunotherapy. Cancer Res 1973; 33: 1987–1997.

    PubMed  Google Scholar 

  175. . Mathé G, Misset JL, Gil-Delgado M, Musset M, Reizenstein P, Canon C.A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patients. Biomed Pharmacother 1986; 40: 383–385.

    PubMed  Google Scholar 

  176. Mathé G, Misset JL, Plagne R, Belpomme D, Guerrin J, Fumoleau P, Metz R, Delgado M. (OncoFrance Comparative trial project): Superiority of AVCF (adriamycin, vincristine, cyclophosphamide and 5-fluorouracil) as adjuvant chemotherapy for breast cancer. A phase III trial of Association OncoFrance In: Tosiru and Voshida, eds. Basic Mechanism and Clinical Treatments of Tumor Metastasis. New York: Academic Press, 1982.

    Google Scholar 

  177. Mathé G, Orbach S. Combination of exogenous immunomodulators. Biomed Pharmacother 1997 in press.

    Google Scholar 

  178. Mathé G, Pouillart P, Lapeyraque F. Active immunotherapy of mouse RC 19 and E female KI leukemias applied after the intravenous transplantation of the tumor cells. Experientia 1971; 27: 446–447.

    Article  PubMed  Google Scholar 

  179. Mathé G, Pontiggia P. Several years beneficial effect of bestatin on white cells and platelets numbers in human myelodysplasia. Biomed Pharmacother 1995 under press.

    Google Scholar 

  180. Mathé G, Pouillart P, Schwarzenberg L, Amiel JL. Attempts at immunotherapy of 100 acute lymphoid leukemia patients. Some factors influencing results. In: Investigation and Stimulation of Immmunity in Cancer Patients. Paris & Heidelberg: CNRS & Springer, 1974:434.

    Google Scholar 

  181. Mathé G, Pouillart P, Schwarzenberg L, Schneider M. Transfusions of lymphocytes from non immunized or immunized donors in mice leukaemia therapy. In White cell Transfusions. Paris: Centre National de la Recherche Scientifique, 1970: 197–201.

    Google Scholar 

  182. Mathé G, Reizenstein P. Intensive cancer chemotherapy and immunotherapy? Biomed Pharmacother 1993; 47: 125–126.

    Article  PubMed  Google Scholar 

  183. Mathé G, Schwarzenberg L. The graft versus host reaction after white blood cell transfusions. In White cell Transfusions. Paris: Centre National de la Recherche Scientifique, 1970: 101–103.

    Google Scholar 

  184. Mathé G, Tran Ba Loc. Effet sur la leucemie L1210 d’une combinaison par diazotation d’A-menothopterine et de gamma-globulines de hamsters porteurs de cette leucemie parheterogreffe. CRAcad Sci 1958; 246: 1626–1627.

    Google Scholar 

  185. Mathé G, Umezawa H, Misset JL, Brienza S, Canon C, Musset M, Reizenstein P. Immunomodulating properties of bestatin in cancer patients. A phase II trial. Biomed Pharmacother 1986; 40: 379–382.

    PubMed  Google Scholar 

  186. Mathé G, Weiner R, Pouillart P. BCG in cancer immunotherapy. I. Experimental and clinical trials of its use in the treatment of leukemia minimum or/and residual disease. Natl Cancer Int Monogr 1973; 39: 165.

    Google Scholar 

  187. Matsuura MY, Watanabe MH, Fukuda T, Yoshida T, Kuroiwa Y. A sustained increase of microsomal heme oxygenase activity following treatment of rats with Bacillus Calmette-Guerin and Corynebacterium parvum: its possible relation to decrease of cytochrome P-450 content. J Pharmacobio-Dynamics 1985; 8: 669–678.

    CAS  Google Scholar 

  188. Mehta J, Powles RL, Treleaven J, Shields M, Agrawal S, Rege K, Mitchell P, Allard S. Cimetidine-induced myelosuppression after bone marrow transplantation. Leuk Lymphoma 1994; 13: 179–181.

    Article  PubMed  CAS  Google Scholar 

  189. Michie HR, FRCS(E), Eberlein TJ, Spriggs DR, Manogue KR, Cerami A, Wilmore DW. Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann Surg 1988; 208: 493–503.

    Article  PubMed  CAS  Google Scholar 

  190. Migliore-Samour D, Delaforge M, Jaouen M, Mansuy D, Jolles P. In vivo effects of immunostimulating lipopeptides on mouse liver microsomal cytochromes P-450 and on paracetamol-induced toxicity. Experientia 1989; 45:882–886.

    Article  PubMed  CAS  Google Scholar 

  191. Moenner M, Barritault D. Les facteurs de croissance et leurs recepteurs. In: Andrieu JM, ed. Biologie des Cancers. Paris: Ellipses, 1994: 33–44.

    Google Scholar 

  192. Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Goodman PJ. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352–358.

    Article  PubMed  CAS  Google Scholar 

  193. Moertel CG, Fleming TR, Mcdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Inter Med 1995; 122: 321–326.

    CAS  Google Scholar 

  194. Moochhala SM. Alteration of drug biotransformation by interferon and host defense mechanism. Annals Acad Med Singapore 1991; 20: 13–18.

    CAS  Google Scholar 

  195. Moore MAS. Growth and maturation factors in leukemia. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker 1991: 525–583.

    Google Scholar 

  196. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2) 180–3.

    PubMed  CAS  Google Scholar 

  197. Najjar VA. The clinical and physiological aspects of tuftsin deficiency syndromes exhibiting defective phagocytosis.Klin Wochensch 1979; 57: 751–756.

    Article  CAS  Google Scholar 

  198. Najjar VA, Constantopoulos A. A new phagocytosisstimulating tetrapeptide hormone, tuftsin, and its role in disease. JReticuloendoth Soc 1972; 12: 197–215.

    CAS  Google Scholar 

  199. Najjar VA, Konopinska D, Chaudhuri MK, Schmidt DE, Linehan L. Tuftsin, a natural activator of phagocytic functions including tumoricidal activity. Mol Cell Biochem 1981;41:3–12.

    PubMed  CAS  Google Scholar 

  200. Najjar VA, Linehan L, Konopinska D. The antineoplastic effects of tuftsin and tuftsinyltuftsin on B 16/5B melanoma and L 1210 cells. Ann NY Acad Sci 1983; 419: 261–267.

    Article  PubMed  CAS  Google Scholar 

  201. Najjar VA, Nishioka K. Tuftsin: A physiological phagocytosis-stimulating peptide. Nature 1970; 228:672–673.

    Article  PubMed  CAS  Google Scholar 

  202. Najjar VA, Nishioka K, Constantopoulos A, Sato PS. The function and interaction of erythrophilic g-globulin with autologous erythrocytes. In: Rapoport S, Jung M, eds. VI Int Sym uber Struktur und Funktion der Erythrozyten. Berlin: Akademi-Verlak, 1972: 355–360.

    Google Scholar 

  203. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immuno-chemotherapy as adjuvant treatment after curative resection of gastric cancer. Study group of immunotherapy with PSK for gactric cancer. Lancet 1994;343:1122–1126.

    Article  PubMed  CAS  Google Scholar 

  204. Neprina GS, Panteleeva ES, Vatin OE, Kariakin OB. The immunomodulating action of bestatin in the combined therapy of bladder cancer patients. Urol Nefrol (Mosk) 1994;2:34–38.

    Google Scholar 

  205. Nishioka K, Constantopoulos A, Sato PS, Mitchell WM, Najjar VA. Characteristics and isolation of the phagocytosis-stimulating peptide tuftsin. Biochem Biophys Acta 1973; 310:217–229.

    PubMed  CAS  Google Scholar 

  206. Nishioka K, Constantopoulos A, Sato P, Najjar VA. The characteristics, isolation and synthesis of the phagocytosis stimulating peptide tuftsin. Biochem Biophys Res Commun 1972; 47: 172–179.

    Article  PubMed  CAS  Google Scholar 

  207. Nishioka K, Sato PS, Constantopoulos A, Najjar VA. The chemical synthesis of the phagocytosis tetrapeptide tuftsin (Thr-Lys-Pro-Arg) and its biological properties. Biochem Biophys Acta 1973; 310: 230–237.

    PubMed  CAS  Google Scholar 

  208. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61:1307–1317.

    PubMed  CAS  Google Scholar 

  209. Nose Y. After therapeutic plasmapheresis extra-corporeal cellular immunomodulation. Artif Organs 1991; 15: 69–73.

    Article  PubMed  CAS  Google Scholar 

  210. Ochiai T. Immunotherapy of gastric cancer. In: Mathé G, Reizenstein P, Dicato M, eds. Clinical Trials in Oncology: Ethics, Errors, Methods and Results. Geneva: Bioscience Ediprint, 1986: II87-95.

    Google Scholar 

  211. Ohno R, Nakamura H, Kodera MY, Ezaki K, Yokomaku S, Oguma S, Kubota Y, Shibata H, Ogawa N, Masoaka T et al. Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogenic AML cells. Cancer 1986; 57: 1483–1488.

    Article  PubMed  CAS  Google Scholar 

  212. Okamura K, Yajima A. Cervical cancer: chemotherapy and immunotherapy. In: Mathe G, Reizenstein P, Dicato M, eds. Clinical Trials in Oncology: Ethics, Errors, Methods and Results. Int J Immunother 1986 II: 101–107.

    Google Scholar 

  213. Okamura S, Ompori F, Haga K, Baba H, Kawasaki C, Tanaka T, Suginachi K, Niho Y. Ubenimex stimulates production of colony-stimulating factor from human peripheral mononuclear cells in vito. In Bestatin 16 ICC Proceedings, Israel, Jerusalem, 1989: (abst)12.

    Google Scholar 

  214. Oleksowicz L, Paciucci PA, Zuckerman D, Colorito A, Rand JH, Holland JF. Alterations of platelet function induced by interleukin-2. J Immmunotherapy 1991; 10: 363–370.

    Article  CAS  Google Scholar 

  215. Olkowski ZL, Jedrzejczak WW. Responses of immune system to hyperthermia. Adv Exp Med Biol 1990; 267: 507–509.

    PubMed  CAS  Google Scholar 

  216. Olsson L, Ebbesen P, Kiger N, Florentin I, Mathé G. The antileukemic effect of systemic nonspecific BCG-immunostimulation versus systemic specific immunostimulation with irradiated isogeneic leukemic cells. Eur J Cancer 1978; 14:355–362.

    Article  PubMed  CAS  Google Scholar 

  217. Olsson L, Florentin I, Kiger N, Mathé G. Cellular and humoral immunity to leukemia in BCG-induced growth control growth of a murine leukemia. J Natl Cancer Inst 1977; 59: 1297–1306.

    PubMed  CAS  Google Scholar 

  218. Olsson L, Kiger N, Mathé G. Autoreactive cells in canceractive immunotherapy: their cytotoxic potential and genetic restriction. Transplantation Proceedings 1980; 12: 167–171.

    PubMed  CAS  Google Scholar 

  219. Olsson L, Kiger N, Mathé G. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980; i: 253.

    Google Scholar 

  220. Olsson L, Mathé G. Antigenic heterogeneity of leukemic cells. Blood Cells 1981; 7: 281–286.

    PubMed  CAS  Google Scholar 

  221. Olsson L, Mathé G. Emerging immunologic approaches to treatment of neoplastic diseases. Recent Results in Cancer Research. Vol 80. Berlin - Heidelberg: Springer- Verlag, 1982.

    Google Scholar 

  222. Olsson L, Mathé G. Immune reaction with cytotoxic activity to ’self’ in natural surveillance of aberrant cells. Biomed Pharmacother 1979; 30:281–282.

    CAS  Google Scholar 

  223. Orbach-Arbouys S, Andrade-Mena CE, Mathé G. Reversal of immunological tolerance by aclacinomycin through inhibition of suppressor cell activity. Cell Immunol 1983; 81: 84–90.

    Article  Google Scholar 

  224. Orbach-Arbouys S, Castes M. Augmentation of immune responses after methotrexate administration. Immunol 1979;36:265–269.

    CAS  Google Scholar 

  225. Ota K. Efficiency of bestatin for acute nonlymphocytic leukemia. A cooperative bestatin chemoimmunotherapy group study. Drugs Exp Clin Res 1984; 10:643–645.

    Google Scholar 

  226. Ota K, Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute non lymphocytic leukemia in adults. Biomed Pharmacother 1990; 44: 93–101.

    Article  PubMed  CAS  Google Scholar 

  227. Otsuka T, Okamura S, Ohhara N, Harada M, Hayashi S, Yamaga S, Omori F, Niho Y. Stimulatory effects of bestatin on human B-cell colony formation. IntJImmunopharmacol 1988; 10: 587–591.

    Article  PubMed  CAS  Google Scholar 

  228. Pagano F, Bassi P, Milani C, Piazza N, Meneghini A, Garbeglio A. BCG in superficial bladder cancer: a review of phase III European trials. Eur Urol 1992; 21 suppl.2: 7–11.

    PubMed  Google Scholar 

  229. Penn I, Halgrimson CG, Starzl TE. De novo malignant tumors in organ transplant recipient. Transpl Proc 1971; 3: 773–778.

    CAS  Google Scholar 

  230. Plagne R. Immunotherapy of melanoma. Int J Immunother 1986; II: 19–21.

    Google Scholar 

  231. Pontiggia P, Barni S, Mathé G, Bertone V, Pontiggia E. Lysosomal exocytosis induced by hyperthermia: a new model of cancer cell death. II. Effects on peritoneal macrophages. Biomed Pharmacother 1995; 49: under press.

    Google Scholar 

  232. Pontiggia P, Mathé G. A new mode of cancer cell death induced by hyperthermia and non specific (macrophagic) cancer immuno-therapy: lysosomal exocytosis. Biomed Pharmacother 1994; 48: 331.

    Article  PubMed  CAS  Google Scholar 

  233. Pouillart P, Palangie T, Schwarzenberg L, Mathé G. Effect of BCG on hamopoietic stem cells. Biomedicine (Express) 1976; 23:469–471.

    Google Scholar 

  234. Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur Urol 1992; 21 suppl.2: 17–21.

    PubMed  Google Scholar 

  235. Reid JW, Cannon GB, Perlin E, Blom J, Connor R, Herberman RB. Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy. Rec Res Cancer Res 1982; 80: 219–226.

    CAS  Google Scholar 

  236. Reizenstein P, Andersson M, Beran M. Possible mechanisms of immunotherapy action in acute non lymphatic leukemia: macrophage production of colonystimulating activity. Rec Res Cancer Res 1982; 80: 64–69.

    CAS  Google Scholar 

  237. Reizenstein P, Andersson M, Bjorkholm M, Brenning G, Engstedt L, Gahrton G, Hast R, Holm G, Hornsten P, Killander A, Lantz B, Lindemalm C, Lockner D, Lonnquvist B, Mellstedt H, Palmblad J, Paul C, Simmonsson B, Sjogren AM, Stalfelt A-M, Uden A-M, Wadman B, Oberg G, Osby E. BCG plus leukemic cell therapy in patients with acute nonlymphoblastic leukemia: effect in groups with high and low remission rates. In: Terry W, Rosenberg S, eds. Immunotherapy of Human Cancer. New York; Excerpta Medica, 1982: 17–22.

    Google Scholar 

  238. Reizenstein P, Delgado M, Gastiaburu J, Lomme L, Ogier C, Pals H, Schellekens J, Whitakker J, Mathé G. Efficacy of an errors in randomized multicenter trials. A review of 230 clinical trials. Biomed Pharmacother 1983; 37: 14–24.

    PubMed  CAS  Google Scholar 

  239. Reizenstein P, Mathé G. Vriz N, Lomme L. Non specific immunomodulators in oncology and hematology. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker, 1991:217–252.

    Google Scholar 

  240. Reizenstein P. The monitoring of minimal residual disease in patients with malignant tumor. In: Reizenstein P, Mathé G, Dicato M. eds. Managing Minimal Malignancy in Man. Oxford: Pergamon Press, 1988.

    Google Scholar 

  241. Resch MK, Goppelt M, Hansch GM, Korner CF, Martin M, Szamel M. Mechanisms of arachidonic acid turnover implicated in cell activation. In Chedid L, Hadden JW, Spreafico F, Dukor P, Willoughby D, eds. Advances in Immunopharmacology 3. Proceeding of the Third International Conference on Immuno-pharmacology. Florence, May 6-9,1985. Pergamon Press, 1986: 115.

    Google Scholar 

  242. Robert P. Le Petit Robert. Paris: Le Robert, 1990.

    Google Scholar 

  243. Rola-Pleszczynski M. Leukotrienes and the immune system. J. Lipid Mediat 1989; 1: 149–159.

    PubMed  CAS  Google Scholar 

  244. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishment and prospects. Cancer Treat Rep 1984; 68:233–235.

    PubMed  CAS  Google Scholar 

  245. Rosenberg SA. Immunotherapy of patients with advanced cancer using recombinant lymphokines. Clin Courrier 1989; 7: 16–20.

    Google Scholar 

  246. Rozengurt E. Stimulation of DNA synthesis in quescient cultured cells. Exogenous agents, internal signals and early event. Curr Top Cell Regal. 1980; 17: 59–88.

    CAS  Google Scholar 

  247. Rutten VP, Klein WR, Steerenberg PA, DeJong WA, DenOtter W, Ruitenberg EJ. Immunotherapy of bovine ocular squamous cell carcinoma : isolation, culture and characterization of lymphocytes present in the tumor. Anticancer Res 1991,11,1259–1264.

    PubMed  CAS  Google Scholar 

  248. Sasaki K, Sasaki M, Ishikawa M, Takayanagi G. Depression of hepatic microsomal enzyme systems by lentinan in mice. Japanese J Pharmacol 1985; 37: 107–115.

    Article  CAS  Google Scholar 

  249. Sato PS, Constantopoulos A, Nishioka K, Najjar VA. Tuftsin, threonyl-lysyl-prolyl-arginine, the phagocytosis stimulating messenger of the carrier cytophillic gammaglobulin leukokinin. In: Meinhoff J, ed. Chemistry and biology of peptide. Ann Arbor: Ann Arbor Science Publ, 1972:403–408.

    Google Scholar 

  250. Satoh K, Kan N, Okino T, Mise K, Yamasaki S, Harada T, Hori T, Ohgaki K, Tobe T. The therapeutic effect of OK- 432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers. Biotherapy 1993;6:41–49.

    Article  PubMed  CAS  Google Scholar 

  251. Sawyer ST, Krantz SB. Erythropoietin stimulates 45Ca2+ uptake in Friend virus-infected erythroid cells. J Biol Chem 1984,259 p: 2769–2774.

    PubMed  CAS  Google Scholar 

  252. Schwartz JC, Cros C. Bestatin and enkephalins. In: Mathé G, Umezawa H, eds. Progress in Cancer Chemo-immunotherapy. Tokyo: Japan Antibiotics Research Association, 1984:243–244.

    Google Scholar 

  253. Schwarzenberg L, Mathé G, Schneider M, Amiel JL, Cattan A, Schlumberger JR. Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet 1966; ii: 365-368.

    Article  Google Scholar 

  254. Scott Ph. IL-12 initiation cytokine for cell-mediated immunity. Science 1993; 260: 496.

    Article  PubMed  CAS  Google Scholar 

  255. Sen A, Fareed GC. Oncogens, antioncogens and growth factors. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker; 1991: 617–635.

    Google Scholar 

  256. Sethi KK, Brandis H. Synergistic cytotoxic effect of macrophages and normal mouse serum on neuraminidase- treated murine leukaemia cells. Eur J Cancer 1973; 9: 809–819.

    Article  PubMed  CAS  Google Scholar 

  257. Shen RN, Lu L, Young P, Shidnia MH, Hornback NB, Boxmeyer HE. Influence of elevated temperature on natural killer cell activity lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells. Int J Radiat Oncol Biol Phys 1994; 29: 921–826.

    Article  Google Scholar 

  258. Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T, Umezawa H. Enhancement of interleukin 1 and interleukin 2 released by ubenimex. J Antibiot 1987; 40: 363–369.

    PubMed  CAS  Google Scholar 

  259. Skipper HE. Kinetic behavior versus response to chemotherapy. Natl Cancer Int Monogr 1971; 34: 2–14.

    CAS  Google Scholar 

  260. Spirer Z, Zakuth V, Orda R, Wiznitzer T. Acquired tuftsin deficiency. In Anon: Abstracts Conf antineoplastic, imunogenic and other effects of the tetrapeptide tuftsin: A natural macrophage activator. New York: Februrary 16- 17,1983 (abstract n° 21).

    Google Scholar 

  261. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 1980; 303: 11431147.

    Article  Google Scholar 

  262. Sporn MB, Robert AB. The transforming growth factor beta: past, present and futur. Ann NY Acad Sci 1990; 593: 1–6.

    Article  PubMed  CAS  Google Scholar 

  263. Stebbing N. Recombinant DNA-derived organisms as sources of cancer biotherapeutics. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Dekker; 1991:73–107.

    Google Scholar 

  264. Steinhorn SC, Ries LG. Improved survival among children with acute leukemia in the United States. Biomed Pharmacother 1988; 42: 675–681.

    PubMed  CAS  Google Scholar 

  265. Stewart WE. The interferon system. New York: Springer, 1971.

    Google Scholar 

  266. Stout SA, Riley CM, Derendorf H. In vitro pharmacokinetics and pharmacodynamics of melphalan. Biennial Conference on Chemo-therapy of Infectious diseases and Malignancies. Munich 26,1987.

    Google Scholar 

  267. Suda H, Takita T, Aoyagi T, Umezawa H. The structure of bestatin. JAntibiot 1976; 29: 100–101.

    CAS  Google Scholar 

  268. Szmigielski S, Sobczynski J, Sokolska G, Stawarz B, Zielinski H, Petrovich Z. Effects of local prostatic hyperthermia on human NK and T cell function. Int J Hyperthermia 1991;7:869–880.

    Article  PubMed  CAS  Google Scholar 

  269. Takahashi SI, Kato H, Sebi T, Takahashi A, Noguchi T, Naito H. Intermediate peptide of insulin degradation in liver and cultures hepatocytes of rats. Int J Biochem 1988; 20: 1369–1380.

    Article  PubMed  CAS  Google Scholar 

  270. Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. Amsterdam: Elsevier North Holland, 1982.

    Google Scholar 

  271. Thomas ED, Storb R, Clift RA, Feffer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckenr CD. Bone marrow Transplantation. N Engl J Med 1975; 292: 832–843.

    Article  PubMed  CAS  Google Scholar 

  272. Thompson RB, Alberola V, Mathe G. Evaluation of surgery, chemotherapy and immunotherapy on the Lewis lung tumor. Rev Eur Etudes Clin Biol 1972; 17: 900–902.

    CAS  Google Scholar 

  273. Treurniet-Donker AD, Meischke-de Jongh ML, vanPutten WL. Levamisole as adjuvant immunotherapy in breast cancer. Cancer 1987; 59: 1590–1593.

    Article  PubMed  CAS  Google Scholar 

  274. Tursz T, Hors J, Lipinski M, Amiel JL, Mathe G. HLA phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL.N Engl J Med 1978; 1:1250.

    CAS  Google Scholar 

  275. Uchida A, Hoshino T. Effect of immunotherapy with OK- 432 in lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 1980; 45:476–483.

    Article  PubMed  CAS  Google Scholar 

  276. Uchida A, Hoshino T. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy. Int J Cancer 1980; 26:401–404.

    Article  PubMed  CAS  Google Scholar 

  277. Uchida A, Micksche M, Hoshino T. Intrapleural administration of OK-432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated larger granular lymphocytes. Cancer Immunol Immunother 1984; 18:5–12.

    Article  PubMed  CAS  Google Scholar 

  278. Ulrich A. Chemotherapy of Advanced Epithelial Cancer. Stuttgart: Hippokrates Verlag, 1990.

    Google Scholar 

  279. Umezawa H. Small molecular microbial products enhancing immune response. Antibiot Chemother 1978; 24: 9–18.

    PubMed  CAS  Google Scholar 

  280. Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. JAntibiot 1976; 29: 97–99.

    CAS  Google Scholar 

  281. VanAmsterdam JG, Llorens-Cortes C. Inhibition of enkephalin degradation by phelorphan: effects on striatal (Met5) enkephalin levels and jump latency in mouse hot plate test. EurJPharm 1988; 154: 319–324.

    Article  Google Scholar 

  282. Vogler WR. Results of randomized trials of immunotherapy for acute leukemia. Cancer Immunol Immunother 1981; 9: 15–21.

    Google Scholar 

  283. Volz M, Kirkpatrick CH. Interferon 1992: How much of the promise has been realised? Drugs 1992; 43: 285–294.

    Article  PubMed  CAS  Google Scholar 

  284. Wakasuki M, Kasahara T, Minato N, Hamuro J, Miyata M, Morioka Y. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: Interferon and interleukin-2 participation in the stimulation with OK-432. J Natl Cancer Inst 1982; 69: 807–812.

    Google Scholar 

  285. Webb D, Braun W, Plescia OJ. Antitumor effects of polynucleotides and theophylline. Cancer Res 1972; 32: 1814–1819.

    PubMed  CAS  Google Scholar 

  286. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graftversus- host disease in human recipients of allogeneic marrow grafts. New Engl J Med 1979; 300: 1068–1073.

    Article  PubMed  CAS  Google Scholar 

  287. Wider J. Randomizing means, not aims in clinical trial. Lancet1994; 343:359.

    Article  Google Scholar 

  288. Wolf G. Multiple functions of Vitamin A. Physiol Rev 1984;64:873–937.

    PubMed  CAS  Google Scholar 

  289. Wolmark N, Fisher B, Rockette H. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30–36.

    Article  PubMed  CAS  Google Scholar 

  290. Zhu HM. Short-term results of intratumor BCG injection for rectal carcinoma. Chung Hua Chung Liu Tsa Chih 1990; 12:40–42.

    PubMed  CAS  Google Scholar 

  291. BCGhelps vaccine fight advanced melanoma. Med Trib 1993: 12.

    Google Scholar 

  292. Interleukin 2 in cancer: select your patients well. Inpharma march 28,1992: 16.

    Google Scholar 

  293. Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood: Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (BCG), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen (Concord Trial). Br Med J1971; 4: 189-194.

    Google Scholar 

  294. WHO.Neoplastic diseases of haematopoietic and lymphoid tissues. Geneve, 1976.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut de Cancérologie et d’Immunologie, 6 rue Minard, BP 60, 92133, Issy-les-Moulineaux Cedex, France

    G. Mathé

  2. Hôpital Suisse de Paris, 10 rue Minard, 92130, Issy-les-Moulineaux, France

    S. Orbach-Arbouys

Authors
  1. G. Mathé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Orbach-Arbouys
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mathé, G., Orbach-Arbouys, S. (1998). Non-Specific Exogenous Immunomodulator in Oncology. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_7

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation